Temasek Holdings has led a $80-million Series B funding round for Chinese biomanufacturing firm Mojia Biotech. Separately, Chinese drug discovery startup Helixon has completed its Series A funding round at almost 500 million yuan (about $75 million).
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
